Filing Flows › Vir Biotechnology (VIR) › R&D spending
Vir Biotechnology (VIR) R&D spending by quarter
Vir Biotechnology's R&D spending was $135M in Q2 2026 (second quarter 2026), +53% from Q4 2025. Over the last 5 quarters it ranged from $88.3M (Q4 2025) to $151M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $135M | +53% | +39% |
| Q4 2025 | $88.3M | -42% | — |
| Q3 2025 | $151M | +55% | — |
| Q2 2025 | $97.5M | -18% | — |
| Q1 2025 | $119M | — | — |
Q2 2026 at a glance
Vir Biotechnology, Q2 2026: revenue $239M (197× year over year), operating margin 30.7%, net earnings $80.1M, operating cash flow $123M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vir Biotechnology's R&D spending?
Vir Biotechnology's R&D spending was $135M in Q2 2026 (second quarter 2026), +53% from Q4 2025.
How has Vir Biotechnology's R&D spending changed?
Over the last 5 quarters it ranged from $88.3M (Q4 2025) to $151M (Q3 2025).